Will Dynamics Change for FOBs with Big Pharma in the Mix?
By Donna Young
Monday, March 2, 2009
There is little argument that follow-on biologics (FOBs) legislation to create an FDA approval pathway for the products will make its way through Congress this year, despite what is sure to be a political fight over the number of years of data exclusivity for innovator products.
Sign up for Perspectives FREE e-mail newsletter.
Outside the U.S.: 1-404-262-5423
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.